Long‐term outcomes of combined intravitreal methotrexate and systemic high‐dose methotrexate therapy in vitreoretinal lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5609
Abstract: The optimal treatment for vitreoretinal lymphoma (VRL) remains a challenge, as central nervous system (CNS) relapse occurs frequently, leading to the worst impact on survival. We previously proposed combined intravitreal methotrexate and systemic high‐dose methotrexate… read more here.
Keywords: combined intravitreal; vitreoretinal lymphoma; systemic high; methotrexate ... See more keywords